Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences (Nasdaq: SLDB) announced on Nov. 4, 2025 that it granted a total of 26,550 restricted stock units (RSUs) to two newly hired employees as inducements under its 2024 Inducement Stock Incentive Plan.
The RSUs vest in four equal annual installments on each one‑year anniversary of the grant date through the fourth anniversary, and vesting is subject to each employee's continued service. The grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) ha annunciato il 4 novembre 2025 di aver concesso in totale 26.550 unità azionarie limitate (RSU) a due dipendenti recentemente assunti come incentivi ai sensi del piano di incentivi azionari per induzione del 2024.
Le RSU maturano in quattro rate annuali uguali ad ogni anniversario della concessione fino al quarto anniversario, e la maturazione è soggetta al continuo servizio da parte di ciascun dipendente. Le concessioni sono state effettuate come incentivi in conformità al Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) anunció el 4 de noviembre de 2025 que concedió un total de 26.550 unidades de acciones restringidas (RSU) a dos empleados recientemente contratados como incentivos conforme al Plan de Incentivos en Acciones por Inducción de 2024.
Las RSU se consolidan en cuatro cuotas anuales iguales en cada aniversario del otorgamiento hasta el cuarto aniversario, y la consolidación está sujeta al continuo servicio de cada empleado. Los premios se otorgaron como incentivos de conformidad con la Regla de Listado 5635(c)(4) de Nasdaq.
Solid Biosciences (나스닥: SLDB)가 2025년 11월 4일 두 명의 신규 채용 직원에게 총 26,550주식 부여 제한 RSU를 2024년 개시 주식 인센티브 계획에 따라 부여했다고 발표했습니다.
RSU는 부여일로부터 매년 같은 비율로 네 차례의 공정한 연도별 분할로 vesting되며, 매 1년의 기념일에 vesting이 완료되고, vesting은 각 직원의 지속적 서비스에 달려 있습니다. 이 보상은 Nasdaq Listing Rule 5635(c)(4)에 따라 inducement로 부여되었습니다.
Solid Biosciences (Nasdaq: SLDB) a annoncé le 4 novembre 2025 avoir accordé au total 26 550 unités d’actions restreintes (RSU) à deux nouveaux employés, en tant qu’incitatifs en vertu du Plan d’Incitation en Actions 2024.
Les RSU vestent en quatre versements annuels égaux à chaque anniversaire d’octroi, jusqu’au quatrième anniversaire, et la vesting est soumise à la poursuite du service par chaque employé. Les attributions ont été émises à titre d’inducement conformément à la Nasdaq Listing Rule 5635(c)(4).
Solid Biosciences (Nasdaq: SLDB) gab am 4. November 2025 bekannt, dass es insgesamt 26.550 RSUs (Restricted Stock Units) an zwei neu eingestellte Mitarbeitende als Anreize gemäß dem 2024 Inducement Stock Incentive Plan gewährt hat.
Die RSUs vesten in vier gleichen jährlichen Teilbeträgen an jedem einjährigen Jubiläum des Gewährungsdatums bis zum vierten Jubiläum, und die Vesting-Bedingung hängt von der fortdauernden Zugehörigkeit des Mitarbeiters ab. Die Zuwendungen wurden als Anreize gemäß der Nasdaq Listing Rule 5635(c)(4) vorgenommen.
Solid Biosciences (المدرَج في ناسداك: SLDB) أعلنت في 4 نوفمبر 2025 أنها منحت إجمالاً 26,550 وحدة أسهم مقيدة (RSUs) لشخصين موظفين جُدد كحوافز بموجب خطة الحوافز بالأسهم لعام 2024.
تستحق RSU في أربع دفعات سنوية متساوية في كل ذكرى تقريبية للا منحها حتى الذكرى الرابعة، وتخضع الاستحقاق لاستمرار خدمة كل موظف. وتم منح الجوائز كحوافز وفقاً لـ قاعدة إدراج ناسداك 5635(c)(4).
- None.
- None.
CHARLESTOWN, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 26,550 restricted stock units (“RSUs”) to two newly hired employees.
The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.
This grant was made pursuant to the Company’s 2024 Inducement Stock Incentive Plan and was made as an inducement material to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
What did Solid Biosciences (SLDB) announce on Nov. 4, 2025 about RSU inducement grants?
How do the RSUs granted by SLDB vest and what is the timeline?
Are the SLDB RSU awards conditional on continued employment?
Under which plan and Nasdaq rule were the SLDB inducement grants made?
How many employees received RSU inducement grants from SLDB on Nov. 4, 2025?
